文献速递妇科

II-IV期内膜癌宫颈间质浸润与分子特征分析

Cervical stromal invasion and molecular characterization in stage II-IV endometrial cancers.
PubMed 文献 · Gynecol Oncol · 2025-01-10

本研究回顾性多中心分析162例合并宫颈间质浸润(CSI)的内膜癌(EC)患者,按分子分型分为NSMP 70例、p53abn 49例、MMRd 40例、POLEmut 3例。单因素分析显示分子分型与术后3年复发显著相关(p=0.04),但校正分期和分级后不再显著(p=0.28)。结论认为分期和分级等传统危险因素仍是决定CSI内膜癌预后的关键。

要点

  • 合并CSI的内膜癌患者中NSMP占43.2%、p53abn占30.2%、MMRd占24.7%、POLEmut占1.9%。
  • 单因素分析分子分型与术后3年复发相关(p=0.04),校正分期和分级后不再显著(p=0.28)。
  • 3年无复发生存率NSMP为59.9%、MMRd为50.6%、p53abn为33.1%。

核心结论

  • 分期和分级等传统危险因素仍是决定合并宫颈间质浸润内膜癌预后的关键。
  • 本研究强调整合分子与形态学特征判断内膜癌预后,尤其应重视子宫内膜样组织学类型。

研究设计与样本

  • 回顾性、多中心综述,纳入合并宫颈间质浸润的内膜癌患者162例。
  • 按分子分型分为POLEmut、MMRd、p53abn和NSMP四类,POLEmut因例数少(3例)被排除后续分析。
  • 采用Kaplan-Meier法估计自手术起3年无复发生存率,并拟合Cox比例风险回归模型校正混杂因素。

主要发现

  • 162例中NSMP 70例(43.2%)、p53abn 49例(30.2%)、MMRd 40例(24.7%)、POLEmut 3例(1.9%)。
  • 单因素分析显示分子分型与术后3年内复发显著相关(p=0.04)。
  • 3年无复发生存率NSMP为59.9%(95%CI 46.1-77.8%),MMRd为50.6%(95%CI 34.9-73.2%),p53abn为33.1%(95%CI 19.7-55.3%)。
  • 校正分期和分级后,分子分型与3年内复发不再显著相关(p=0.28)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • POLEmut病例仅3例,因例数少被排除后续分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The optimal treatment for patients with cervical stromal invasion (CSI) in endometrial cancer (EC) remains unclear. We aimed to test the prognostic role of molecular classification in EC patients with CSI. METHODS: A retrospective, multicenter review of EC patients with CSI was performed. EC cases were assigned to one of the molecular classes: POLE mutated (POLEmut), MMR deficient (MMRd), p53 abnormal (p53abn), or no specific molecular profile (NSMP). Three-year recurrence-free survival (RFS) from surgery was estimated using the Kaplan-Meier method. Cox proportional hazards regression models were fit to adjust for confounders. RESULTS: Overall, 162 EC patients with CSI were identified: 70 (43.2 %) NSMP, 49 (30.2 %) p53abn, 40 (24.7 %) MMRd, 3 (1.9 %) POLEmut. POLEmut cases were excluded from further analysis, because of the small number of patients identified. At univariate analysis, molecular class was significantly associated with recurrence within 3 years after surgery (p = 0.04). Three-year RFS was 59.9 % (95 % confidence interval [CI], 46.1-77.8 %) for NSMP, 50.6 % (95 % CI, 34.9-73.2 %) for MMRd, and 33.1 % (95 % CI, 19.7-55.3 %) for p53abn. After adjusting for stage and grade, molecular class was no longer significantly associated with recurrence within three years (p = 0.28). CONCLUSIONS: Traditional risk factors such as grade and stage remain critical in determining the prognosis of endometrial cancer with cervical stromal invasion. This study highlights the importance of integrating both molecular and morphological features in determining the prognosis of endometrial cancer, with particular emphasis on endometrioid histotypes.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. De Vitis LA, Reyes-Baez FE, Schivardi G, et al. Cervical stromal invasion and molecular characterization in stage II-IV endometrial cancers. Gynecol Oncol. 2025. PMID: 39798193. doi:10.1016/j.ygyno.2024.12.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。